Navigation Links
CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application
Date:6/17/2008

men were primarily hematologic, including neutropenia, thrombocytopenia and anemia. Infusion-related toxicities were associated with pre-administration of rituximab. The risk of hematologic toxicity correlated with the degree of bone marrow involvement prior to Zevalin therapy. Myelodysplasia or acute myelogenous leukemia was observed in 2 percent of patients (8 to 34 months after treatment). Zevalin should only be used by health care professionals qualified by training and experience in the safe use of radionuclides.

Patients and healthcare professionals can visit http://www.zevalin.com for more information.

About Non-Hodgkin's Lymphoma

Non-Hodgkin's lymphoma (NHL) is caused by the abnormal proliferation of white blood cells and normally spreads through the lymphatic system, a system of vessels that drains fluid from the body. NHL can be broadly classified into two main forms -- aggressive NHL, a rapidly spreading acute form of the disease, and indolent NHL, which progresses more slowly. According to the SEER CanQuest Database and the American Cancer Society, in 2005, the prevalence of indolent NHL in the United States was 282,025 with 24,490 newly diagnosed patients. The prevalence of aggressive NHL in the United States was 99,880 with 31,900 newly diagnosed patients.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.celltherapeutics.com.

On Wednesday, June 18, 2008, at 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific, members of Cell Therapeutics, Inc.'s (CTI) (Nasdaq:

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Microchip Biotechnologies, Inc. Enters Into License Arrangement With GE Healthcare for Fundamental Microfluidic Patents
2. Alta Bates Summit Medical Center Opens Two Warm, Supportive Patient Centers: Carol Ann Read Breast Health Center and Family Resource Center
3. CyberKnife Radiosurgery Used to Treat Lung Tumors at 90 Percent of Centers Worldwide
4. Chromos enters into loan and lending arrangements
5. Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
6. CSC Continues Support of Centers for Disease Control and Prevention Through New Task Order
7. STAAR Surgicals Collamer(R) IOL Designated as a New Technology Intraocular Lens by the Centers for Medicare and Medicaid Services
8. SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA-Rich Safflower Oil
9. Highmark Blue Cross Blue Shield and National Association Name Area Hospitals as Blue Distinction Centers for Complex and Rare Cancers
10. Finesse Solutions Expands by Opening Sales and Service Centers
11. Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... (PRWEB) October 30, 2014 Whitehouse Laboratories ... its ICH Stability Testing and Package Test Capacity. Responding ... centers on a dramatic increase in environmental chamber storage ... stability, storage and aging samples to be securely held ... this major capital expenditure has already taken place with ...
(Date:10/30/2014)... , Oct. 30, 2014 Isis Pharmaceuticals, Inc. ... today announced that management will present a company overview at ... 8:30 a.m. ET in Boston, MA. ... available on the "Investors & Media" section of the Company,s ... the Isis website within 48 hours and will be archived ...
(Date:10/30/2014)... solution to one of the key challenges in the ... of Sussex physicists. , In a paper published today ... Garraway and colleagues show how to make a new ... Quantum technology devices, such as high-precision sensors and specialised ... of atoms. But the methods for trapping these tiny ...
(Date:10/27/2014)... October 27, 2014 The new ... Type (High & Medium), Sub-type (Primary & Secondary), ... Infrastructure & Transportation & Power Generation) - Trends ... GIS market with analysis and forecasting of the ... Data Tables with 52 Figures spread through 146 ...
Breaking Biology Technology:Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4
... Accelerate Anesiva,s Penetration of the Hospital Market with ... ... FRANCISCO, Calif. and SCHAUMBURG, Ill., Oct. 11, Anesiva, Inc. (Nasdaq: ... Sagent will,co-promote for three years Anesiva,s Zingo(TM) (lidocaine hydrochloride,monohydrate) powder intradermal ...
... England, October 11 Oxford Genome Sciences (UK),Ltd ... its Scientific,Advisory Board (SAB) with the appointment of ... Immunogenetics Laboratory in the Weatherall,Institute of Molecular Medicine ... the fundamental genetic and biological changes which,lead to ...
... Oct. 11 Solstice Neurosciences, Inc.,("Solstice") announced the ... of,Directors. Mr. Smith will serve as Executive Chairman ... served as Chairman since Solstice,was founded in July ... industry experience,and expertise to Solstice that will be ...
Cached Biology Technology:Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals 2Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals 3Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals 4Sir Walter Bodmer Joins Oxford Genome Sciences Scientific Advisory Board 2Sir Walter Bodmer Joins Oxford Genome Sciences Scientific Advisory Board 3Dennis L. Smith Appointed Executive Chairman to Board of Directors of Solstice Neurosciences, Inc. 2
(Date:10/29/2014)... industrial products are in the environment – and hundreds ... scientists have yet to determine whether they cause health ... that by estimating which substances people are exposed to ... ACS journal Environmental Science & Technology . , ... to human health of any given substance depend primarily ...
(Date:10/29/2014)... . Meiosis ... at the Max F. Perutz Laboratories (MFPL) of the ... dived into the process of meiosis in specific plant ... of the standard meiotic phases. The researchers describe the ... . , Meiosis is the two-step series of cell ...
(Date:10/29/2014)... the living world compete with members of their ... much they invest into their competitive ability. Some ... access to high-quality resources, while others seem to ... lower-quality resources that are left over for them. ... human societies seems to fluctuate considerably over time. ...
Breaking Biology News(10 mins):Meiotic cell division 'the other way round' 2Evolution of competitiveness 2Evolution of competitiveness 3
... have isolated a new peptide antibiotic from the ... many diseases in oysters. , The new antimicrobial ... bacteria in Crassostrea virginica, a species that is ... Atlantic and Gulf Coast fisheries. , "This peptide ...
... Mitragotri, a professor of chemical engineering at the University ... injections have led to active research and development of ... prefer to avoid injections, the stakes are enormously higher ... a needle. In third world countries, improper and unsafe ...
... formation follows a dynamic pattern, allowing for retrieval from different ... to remember, said a researcher at Baylor College of Medicine. ... molecular and cellular biology at BCM, theorizes, based on his ... trace in Drosophila or fruit flies is formed in a ...
Cached Biology News:Tracking the memory trace 2
See product name for description....
... 20 Amino Acid length max , MS-spec check ... customer for future usage conjugation of peptide to KLH protein , ... days/each , Pre-immune bleed x1 /each ... Test bleed (app. 5 ml) x1 /each , ...
... following: , Coated Capture Antibody: 12 x 8-well ... 300 mL of 2X concentrate , Beta ... peptide , Lyophilized Standard Diluent: 3 mL , ... Secondary Antibody-HRP: 30 microL of concentrate , OPD ...
Human Cell Line Slides...
Biology Products: